1-4 of 4
Aya Kita
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A165: Result of a phase 1 (dose-escalation stage), first-in-human study of ASP5878, an oral FGFR inhibitor, in patients with advanced solid tumors

Toshio Shimizu, Toshihiko Doi, Noboru Yamamoto, Haruyasu Murakami, Junji Furuse, Koji Kawai, Hiroyuki Nishiyama, Satoshi Morita, Shunji Takahashi, Erkut Bahceci, Joyce Steinberg, Howard A. Ball, Futoshi Kunieda, Kentaro Takeda, Aya Kita, Shigeru Takeshita
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A165.
https://doi.org/10.1158/1535-7163.TARG-15-A165
Published: 01 December 2015
View article titled, Abstract A165: Result of a phase 1 (dose-escalation stage), first-in-human study of ASP5878, an oral FGFR inhibitor, in patients with advanced solid tumors
Journal Articles

Overcoming Erlotinib Resistance in EGFR Mutation–Positive Non–Small Cell Lung Cancer Cells by Targeting Survivin

Kunio Okamoto, Isamu Okamoto, Erina Hatashita, Kiyoko Kuwata, Haruka Yamaguchi, Aya Kita, Kentaro Yamanaka, Mayumi Ono, Kazuhiko Nakagawa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (1): 204–213.
https://doi.org/10.1158/1535-7163.MCT-11-0638
Published: 09 January 2012
View article titled, Overcoming Erlotinib Resistance in <em>EGFR</em> Mutation–Positive Non–Small Cell Lung Cancer Cells by Targeting Survivin
Open the PDF for Overcoming Erlotinib Resistance in <em>EGFR</em> Mutation–Positive Non–Small Cell Lung Cancer Cells by Targeting Survivin in another window
Includes: Supplementary data
Journal Articles

Abstract C104: High in vitro sensitivity of pediatric solid and hematological malignancies to the survivin-suppressant YM155.

Arnauld C. Verschuur, Claudia Lanvers-Kaminsky, Jan J. Molenaar, Fieke G. Lamers, Taufik Ouatas, Aya Kita, Joachim Boos, Gilles Vassal, Huib C. Caron
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C104.
https://doi.org/10.1158/1535-7163.TARG-11-C104
Published: 12 November 2011
View article titled, Abstract C104: High in vitro sensitivity of pediatric solid and hematological malignancies to the survivin-suppressant YM155.
Journal Articles

Concomitant and sequential administration of YM155 and docetaxel enhances apoptosis and tumor regression in human tumor xenograft models

Kentaro Yamanaka, Takahito Nakahara, Aya Kita, Masahiro Takeuchi, Isao Kinoyama, Akira Matsuhisa, Hiroshi Koutoku, Masao Sasamata
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B278.
Published: 01 November 2007
View article titled, Concomitant and sequential administration of YM155 and docetaxel enhances apoptosis and tumor regression in human tumor xenograft models